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Abstract
Background: Glutathione S-transferase P1 (GSTP1) has been reported to function as a tumor suppressor gene in
various types of human cancers. Aberrant methylation of tumor-related genes at the promoter regions can inactivate
genes, which is important in the carcinogenesis of breast cancer. However, the role of GSTP1 promoter methylation in
the occurrence of breast cancer and its relationship with tumor stage and histological grade has not been fully
elucidated. Thus, we carried out a meta-analysis to yield a more accurate association.
Methods: A systematically literature search was made on PubMed, EMBASE and Web of Science databases for eligible
studies. The odds ratio (OR) and 95 % confidence interval (95 % CI) were calculated by RevMan 5.2 software. Subgroup
and sensitivity analyses were conducted to explore the source of heterogeneity.
Results: Eventually, 17 articles involving 19 case–control studies were included in the present meta-analysis. Overall,
the pooled results indicated that aberrant GSTP1 promoter methylation was significantly associated with the risk of
breast cancer (OR = 7.85, 95 % CI = 5.12–12.01; Caucasians OR = 7.23, 95 % CI = 3.76–13.90 and Asians OR = 11.71,
95 % CI = 5.69–24.07). Furthermore, our results revealed that GSTP1 promoter methylation was more often
observed in late-stage breast cancer patients compared with early-stage ones (OR = 1.84, 95 % CI = 1.32–2.58).
However, no significant association was identified between GSTP1 promoter methylation and histological grade
(OR = 0.74, 95 % CI = 0.43–1.26).
Conclusions: The results indicated that GSTP1 promoter methylation probably plays an important role in breast
carcinogenesis, which could serve as an effective biomarker for the diagnosis and monitor of breast cancer.
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Background
Breast cancer, a heterogeneous disease, is by far the most
common malignancy that affects females. It has been
reported that an estimated 1.7 million new cases of breast
cancer were diagnosed with nearly 522,000 related deaths
worldwide in 2012 [1]. Moreover, incidence rates differ
between regions with a lifetime risk of 1 in 3 women in
Asia and 1 in 8 women in the United States [2]. Despite
intensive research, the molecular mechanism of cancer
development is still not fully understood. Generally, the
interplay between genetic and environmental risk factors
has played an important role in the etiology of breast
cancer [3]. In recent years, increasing evidence has shown
that epigenetic changes of tumor-related genes are in-
volved in the pathogenesis and development of breast can-
cer, and could be used as indicators of cancer diagnosis
and treatment [4–6].
Glutathione-S-transferases (GSTs) are a family of en-
zymes involved in the detoxification of carcinogenic and
cytotoxic substances by catalyzing their conjugation with
reduced glutathione [7, 8]. Among the isoenzymes, the
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pi-class GST (GSTπ) encoded by the GSTP1 gene is im-
plicated in a large variety of detoxification and metabol-
ism reactions, which prevent cells from genome damage
and cancer initiation [9, 10]. The GSTP1 gene is a tumor
suppressor gene and locus on chromosome 11q13 [11].
Aberrant methylation of the GSTP1 often occurs in dif-
ferent cancer types including those of liver, prostate, and
breast cancer [12, 13]. Moreover, the silencing of GSTP1
gene expression induced by promoter methylation has
been found to be implicated in the pathogenesis of
breast cancer [14].
To date, several studies have investigated the methyla-
tion patterns of the GSTP1 in breast cancer patients, yet
the data are greatly variable due to differences among
studies. Therefore, we conducted a meta-analysis of the
published clinical studies to evaluate the effect of GSTP1
promoter methylation on breast cancer patients.
Methods
Eligible criteria
Eligible studies included in this meta-analysis should
meet the following standards: (1) assessed the associ-
ation between GSTP1 promoter methylation and breast
cancer; (2) independent case–control studies; (3) all pa-
tients met the clear diagnostic criteria for breast cancer;
(4) provided sufficient data about the methylation levels
of GSTP1 in tissue or blood samples of cancer patients
and normal controls; (5) the methylated GSTP1 was de-
tected by polymerase chain reaction (PCR) based methy-
lation assays.
Literature search
This meta-analysis was reported according to the checklist
of the Meta-analysis of Observational Studies in Epidemi-
ology (MOOSE) guidelines (Additional file 1: Table S1). We
systematically searched related clinical studies regarding the
association between GSTP1 promoter methylation and
breast cancer via PubMed, EMBASE and Web of Science
databases (up to January 31, 2015). The key terms: (breast
OR mammary) And (cancer OR neoplasm OR tumor OR
carcinoma) And (GSTP1 OR glutathione S-transferase P1)
And (methylation OR hypermethylation) were used. The
references cited in the selected studies were also scanned
for relevant studies.
Data extraction
Data extraction was conducted independently by two re-
viewers from the included studies. The recorded informa-
tion for each study contained the following: First author’s
name, year of publication, patients’ ethnicity, sample type,
sample size, tumor stage, histological grade, GSTP1
methylation frequencies and the methylation detection
methods. All selected studies used normal samples as con-
trols, which were composed of normal breast tissues from
breast cancer patients and normal samples from non-
cancer people. Of these studies, we combined stage 0, I
and II as early-stage, stage III and IV as late-stage, which
were defined by AJCC staging system [15]. As for histo-
logical grade, Grade I and II were defined as low-grade,
Grade III was defined as high-grade [16].
Statistical analysis
Odds ratios (ORs) and their 95 % confidence intervals
(CIs) were used to evaluate the association. Heterogeneity
was quantified by the Cochran Q test with statistical
significance set at P < 0.10 and I2 statistics. If there was
no statistical heterogeneity among studies (P ≥ 0.10 and
I2 < 40 %), we used the fixed-effect model to pool the
results; otherwise, the random-effects model was ap-
plied [17]. Moreover, subgroup analyses, which were
stratified according to the patients’ ethnicity, sample type
and detection methods were performed to explore poten-
tial sources of heterogeneity and the differences among
them. In the presence of heterogeneity, sensitivity ana-
lysis was conducted by omitting a single study in each
turn to see whether a particular omission could influ-
ence the overall estimate. The funnel plots were applied
to assess publication bias if the included number of
studies was no less than nine. All above analyses were
carried out using the Review Manager 5.2 software
(Cochrane Collaboration, Oxford, UK). In addition, the
effect of possible publication bias was evaluated using
the Egger’s test [18] and trim-and-fill method [19] by
STATA 12.0 software.
Results
Studies selection and characteristics
After being selected in accordance with our inclusion cri-
teria, 17 articles involving 19 case–control studies [20–36],
comprising 1,647 cases and 559 controls were finally
included, the publication years of the selected studies
ranged from 2003–2014. Figure 1 showed the process
of study selection.
Ten studies were conducted among Caucasians
[20, 21, 24–26, 28, 30, 32, 35, 36], seven studies
among Asians [23, 29, 31, 33, 34], one study among
Africa [22] and the other one was among mixed popula-
tions [27]. Tumor tissues and blood samples were used to
detect the methylation status of GSTP1 promoter. More-
over, the methylated levels of GSTP1 were assessed
using a variety of PCR based methylation assays com-
posing of methylation-specific PCR (MSP), quantitative
MSP (QMSP), pyrosequencing, MethyLight assay, and
methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA). Characteristics of all included
studies were summarized in Table 1.
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Overall and subgroup analyses
Our results showed that breast cancer exhibited signifi-
cantly higher frequency of GSTP1methylation than normal
controls (OR = 7.85, 95 % CI = 5.12–12.01, Fig. 2). More-
over, subgroup analyses were performed to identify the in-
fluence of abnormal GSTP1 promoter methylation on the
risk of breast cancer. Ethnicity-stratified analysis revealed
that there were statistical associations between GSTP1 pro-
moter methylation and increased breast cancer risk among
both Caucasians (OR = 7.23, 95 % CI = 3.76–13.90) and
Asians (OR = 11.71, 95 % CI = 5.69–24.07). After stratified
by sample type, we found that aberrant methylation of
GSTP1 was correlated with the risk of breast cancer
detected in tissue (OR = 10.32, 95 % CI = 5.97–17.85) as
well as blood samples (OR = 4.02, 95 % CI = 1.12–14.38).
After stratified by method, significant associations be-
tween GSTP1 promoter methylation and the risk of
breast cancer were observed in all of the subgroups (Quan-
titative: OR = 4.73, 95 % CI = 1.84–12.12; Semi-quantitative:
Table 1 Main characteristics of included studies




Methods (techniques) GSTP1 (M/N) Stage (M/N) Grade (M/N)
Cacer Normal Early-stage Late-stage Low-grade High-grade
Jeronimo 2003 [20] Caucasian Tissue 27/12 MSP (Non-quantitative) 17/27 0/12 - - - -
Shinozaki 2005 [21] Caucasian Tissue 151/10 MSP (Non-quantitative) 32/151 0/10 - - - -
Hoque 2006 [22] African Blood 90/38 QMSP (Quantitative) 12/47 0/38 6/24 22/66 - -
Lee 2007 [23] Asian Tissue 85/15 MSP+ (Non-quantitative) 32/85 0/15 - - - -
Pasquali 2007 [24] Caucasian Tissue 15/15 Pyrosequencing
(Quantitative)
9/15 2/15 - - - -
Jeronimo 2008 [25] Caucasian Tissue 66/12 QMSP (Quantitative) 33/66 2/12 - - - -
Hoque 2009 [26] Caucasian Tissue 112/32 QMSP (Quantitative) 22/112 3/32 - - - -
Brooks 2010 [27] Mixed Blood 50/99 QMSP (Quantitative) 2/50 7/99 - - - -
Matuschek 2010 [28] Caucasian Blood 76/16 MethyLight assay
(Quantitative)
14/76 1/16 3/39 9/31 - -
Sharma 2010 [29] Asian
Tissue 100/15
MSP (Non-quantitative)
25/100 1/15 8/51 17/49 15/48 8/28
Blood 100/30 22/100 1/30 6/51 16/49 13/48 8/28
Moelans 2011 [30] Caucasian Tissue 72/9 MS–MLPA
(Semi-quantitative)
32/72 0/9 - - 4/25 4/14
Park 2011 [31] Asian Tissue 85/30 MethyLight assay
(Quantitative)
25/85 0/30 - - 6/30 8/20
Kornegoor 2012 [32] Caucasian Tissue 108/10 MS–MLPA
(Semi-quantitative)
47/108 0/10 - - - -
Yamamoto 2012 [33] Asian Tissue 94/53 MSP+ (Non-quantitative) 45/94 1/53 26/56 19/38 - -
Blood 159/87 21/159 2/87 3/68 9/57 - -
Jung 2013 [34] Asian Tissue 60/60 MS–MLPA
(Semi-quantitative)
10/60 2/60 10/53 0/7 6/40 4/20
Klajic 2013 [35] Caucasian Tissue 219/6 Pyrosequencing
(Quantitative)
142/219 0/6 53/85 74/108 - -
de Groot 2014 [36] Caucasian Tissue 21/10 Gel-based MSP
(Semi-quantitative)
9/21 0/10 - - - -
MSP methylation-specific PCR, QMSP quantitative MSP, MS-MLPA methylation-specific multiplex ligation-dependent probe amplification, MSP+ based on MSP with
slight modifications, M the number of methylations, N number of total
Fig. 1 The flow diagram of the study selection process
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OR = 10.33, 95 % CI = 3.32–32.10; Non-quantitative:
OR = 12.55, 95 % CI = 5.72–27.55). Above results could
be reviewed in Table 2.
In addition, eight studies [22, 28, 29, 33–35] comprising
832 patients were pooled for the OR in evaluating the
association between GSTP1 methylation and tumor stage.
The results revealed that aberrant GSTP1 methylation was
more often observed in late-stage patients compared with
early-stage ones (OR = 1.84, 95 % CI = 1.32–2.58, Fig. 3).
However, the pooled OR of five studies showed that there
was no significant association between GSTP1 methylation
and histological grade (OR = 0.74, 95 % CI = 0.43–1.26)
(Table 3).
Sensitivity analysis
The results showed that moderate heterogeneity existed in
investigating the correlation of GSTP1 methylation and
breast cancer risk detected in blood samples and quantita-
tive method by subgroup analysis (Table 2). Then, a sensi-
tive analysis was used to find the heterogeneous study.
After removal of the study by Brooks et al. [27], the
heterogeneity presented in blood samples was reduced
from I2 = 54 % (Ph = 0.07) to I2 = 0 % (Ph = 0.71), the het-
erogeneity in quantitative method was also reduced from
I2 = 45 % (Ph = 0.08) to I2 = 0 % (Ph = 0.43), suggesting it
might be the heterogeneous study. However, the pooled
ORs were not significantly changed in sensitivity analyses,
in which each study was deleted at one time, suggested
the stability of our results.
Publication bias
Visual inspection of the funnel plot in Fig. 4 shows an
asymmetry, which indicates the presence of publication
bias in evaluating GSTP1 methylation and breast cancer
risk. Egger’s test also display statistical evidence of
Fig. 2 Forest plot of the association between GSTP1 methylation and breast cancer risk based on a fixed-effect model. The squares and horizontal
lines correspond to the OR and 95 % CI
Table 2 Overall and subgroups analyses of GSTP1 methylation
and breast cancer risk
Study groups Number OR (95 % CI) Heterogeneity
Ph I2 (%) χ2
Overall 19 7.85 (5.12, 12.01) 0.20 21 22.69
Ethnicity
Caucasians 10 7.23 (3.76, 13.90) 0.67 0 6.65
Asians 7 11.71 (5.69, 24.07) 0.61 0 4.53
Sample type
Tissue 14 10.32 (5.97, 17.85) 0.58 0 11.39
Blood 5 4.02 (1.12, 14.38) 0.07 54 8.64
Method
Quantitative 8 4.73 (1.84, 12.12) 0.08 45 12.84
Semi-quantitative 4 10.33 (3.32, 32.10) 0.86 0 0.77
Non-quantitative 7 12.55 (5.72, 27.55) 0.61 0 4.51
N number of trials, OR odds ratio
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asymmetry (P = 0.003). Then, the trim-and-fill method
was applied to adjust this bias and calculate the number
of unpublished studies that could lead to asymmetry
(Fig. 5). The estimated OR adjusted by trim-and-fill
method was similar to the original estimate (OR = 4.20,
95 % CI = 2.75–6.41), indicating that our analyses were
reliable and robust. For limited number of studies, the
investigation of publication bias with tumor stage and
histological grade were not examined.
Discussion
GSTP1 is a member of the metabolic enzymes family,
which has significant implications in the prevention of
cancer initiation upon exposure to carcinogens [11, 13].
Absence of GSTP1 expression is found in approximately
two thirds of the patients with breast cancer, suggesting it
might play an important role in breast carcinogenesis [23].
It has also been demonstrated that the hypermethylation
of GSTP1 gene promoter frequently occurs in breast can-
cer and may result in inactivation of GSTP1 expression,
thus lead to cancer progression [13].
The current meta-analysis demonstrated that the methy-
lation level of GSTP1 was significantly higher in breast
cancer patients than that in normal controls, which indi-
cated its potential role in the etiology of breast cancer.
This was in accordance with the results of previous stud-
ies [22–24]. We also performed subgroup analyses to fur-
ther explore the potential effects of the patients’ ethnicity,
sample type and detection method on the association of
GSTP1 promoter methylation with the risk of breast can-
cer. The results revealed that GSTP1 promoter methyla-
tion was closely associated with the risk of breast cancer
in both Caucasians (OR = 7.23, 95 % CI = 3.76–13.90) and
Asians (OR = 11.71, 95 % CI = 5.69–24.07), whereas, the
correlation was stronger in Asians than in Caucasians.
The reasons might include differences in genetic back-
grounds, environments and sample size. After stratified by
sample type, we found that aberrant methylation of
GSTP1 was correlated with the risk of breast cancer
detected in tissue (OR = 10.32, 95 % CI = 5.97–17.85) as
well as blood samples (OR = 4.02, 95 % CI = 1.12–14.38).
Moreover, a high concordance between tumor and blood
DNA methylation of GSTP1 was reported in studies con-
ducted on paired tumor tissue and blood samples from
breast cancer patients [29, 33]. Yamamoto et al. compared
the gene methylation status in serum DNA before and after
surgery in patients with primary breast cancer, and demon-
strated that the origin of blood methylated DNA was the
tumor tissue because patients with aberrant GSTP1 methy-
lation in serum DNA collected before surgery were found
to be negative for gene methylation after surgery [33]. This
indicated that blood DNA methylation of GSTP1 could
reflect alterations in the tumor and the ease of obtaining
blood samples makes it a potential biomarker for diagnosis
of breast cancer. In the present meta-analysis, the small
number of patients, various ethnicity groups and different
time of sample collection may contribute to relatively ex-
tended confidence intervals. To date, a diversity of PCR
based methylation assays were developed and widely used
to measure methylation in clinical specimens, classified as
quantitative, semi-quantitative and non-quantitative tech-
niques [37]. Several papers have compared MS–MLPA
(semi-quantitative) with pyrosequencing (quantitative) or
MSP (non-quantitative) and showed a good concordance
between MS–MLPA and pyrosequencing [30, 37]. Since
different methylation assays were applied to detect the
methylation levels of GSTP1 in the studies included in this
Fig. 3 Forest plot of the association between GSTP1 methylation and tumor stage based on a fixed-effect model. OR and 95 % CI were calculated
Table 3 Association of GSTP1 methylation and tumor stage/
histological grade in breast cancer
Study
groups
Number OR (95 % CI) Heterogeneity
Ph I2 (%) χ2
Stage 8 1.84 (1.32, 2.58) 0.20 29 9.81
Grade 5 0.74 (0.43, 1.26) 0.69 0 2.27
N number of trials, OR odds ratio
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meta-analysis, we also performed subgroup analysis based
on methods to explore potential sources of heterogeneity
and the differences among them. As a result, significant
associations were identified as detected by quantitative,
semi-quantitative and non-quantitative techniques, sug-
gested these methods have the same effect in GSTP1
methylation detection. However, when only quantitative
analyses of GSTP1 promoter methylation in blood
DNA are pooled, no significant association was ob-
served (data not shown). It is hypothesized that the
small sample size may lead to false-negative results.
Furthermore, different patient materials and the choice
of different primer sets between different studies may
influence the results. Aberrantly methylated genes are
frequently found in human cancers but rarely in normal
controls, and their presence is not an exclusive attri-
bute of metastatic cancer. Examination of body fluid
from patients with early stage or organ-confined tu-
mors may also reveal positive results [28]. Our study
showed that the methylation level of GSTP1 increased
significantly in late-stage compared to the early stage
breast carcinomas, suggested that breast cancer pa-
tients with GSTP1 promoter hypermethylation may
have a biologically aggressive phenotype.
Breast cancer is a complex multifactorial disease that
is driven by genetic and epigenetic alterations, which
cause aberrant gene function [38]. Previous study de-
clared that the genetic variation of GSTP1 affected its
Fig. 4 Funnel plot for evaluating publication bias test for GSTP1 methylation and breast cancer risk. The standard error of log (OR) of each study
was plotted against its log (OR)
Fig. 5 Funnel plot of publication bias test for GSTP1 methylation and breast cancer risk after trim-and-fill method. Logor natural logarithm of OR,
horizontal line mean effect size
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enzymatic activity and detoxifcation ability, thereby con-
tributing to breast cancer susceptibility [10]. Epigenetic
alterations including DNA methylation and histone modi-
fications which occur in transformed cells are identified as
an early event during tumor development [35, 39]. In
breast cancer, hypermethylation of promoter CpG
islands has been described as the main epigenetic path-
way to inactivate genes involved in various aspects of
cellular function [30]. It has been reported that GSTP1
is capable of inhibiting tumor growth by its interaction
with the c-Jun N-terminal kinase (JNK1) signaling [11],
suggesting its role as a tumor suppressor gene. Add-
itionally, because of its detoxifying effects on the anti-
cancer agents, GSTP1 may also affect the sensitivity of
breast tumors to chemotherapy, emerged as a novel
therapeutic target [7, 9].
To our knowledge, this is the first meta-analysis
comprehensively performed to assess the relationship
between GSTP1 promoter methylation and the inci-
dence of breast cancer. Nevertheless, a number of po-
tential limitations should be acknowledged. First, the
effects of potential risk factors such as age, subtype and
hormone receptor status on the current results of this
meta-analysis could not be eliminated for lack of de-
tailed information. Second, meta-analysis is a second-
ary analysis and the heterogeneity is the major issue in
genetic studies [40–43]. Of course, our meta-analysis
also suffered this issue and we performed subgroup
analyses to explore the origin. The results showed that
different methylation methods, source of controls and
cut-offs positivity of hypermethylation might contrib-
ute to heterogeneity. Third, only published clinical
studies were selected in this meta-analysis, some un-
published and negative studies may contribute to publi-
cation bias. Since studies with statistically positive
results were easier to publish than those with negative
results, publication bias is inevitable. However, the esti-
mated OR adjusted for publication bias by trim-and-fill
method was not substantially changed. Fourth, al-
though our initial search has no language restrictions,
only articles published in English and Chinese finally
were reviewed. This due to the language ability and the
right to use databases of our team, and also might re-
sult in some bias.
Conclusions
In conclusion, our meta-analysis suggested a strong asso-
ciation between GSTP1 promoter methylation and breast
cancer risk. Thus, aberrant GSTP1 promoter methylation
could be a helpful biomarker for the early screening of
breast cancer. However, given the limitations elaborated
above, high quality studies with larger sample sizes should
be employed in further research.
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